Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidates are APR-1051, an orally bioavailable small-molecule inhibitor of WEE1 kinase that is in Phase 1 clinical trial for the treatment of patients with advanced solid tumors with biomarkers and ATRN-119, an ATR inhibitor, which is in Phase 1/2a clinical trial for solid tumor indications. The company is headquartered in Doylestown, Pennsylvania.…
Aprea Therapeutics to Present at the Guggenheim 3rd Annual Healthcare Innovation Conference
Aprea Therapeutics (NASDAQ: APRE) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 8 employees.
The shares were at 0.2290 USD on 20 November 2026, down 81.4% over 52 weeks. Its 52-week range is 0.2036 USD to 1.490 USD: the price is 84.6% below the high and 12.5% above the low.
Its market capitalisation is 3.25M USD.
Aprea Therapeutics reports return on equity of -101.3%.
It holds more cash than debt, a net cash position of 37.85M USD. Its Piotroski F-score is 0 out of 9, a weak reading of its financial health.